Vyndaqel patent expiration?

When does the Vyndaqel patent expire?

The exact “Vyndaqel” (tafamidis) patent expiration date depends on which specific patent(s) covering the drug and its formulations you mean (for example, composition-of-matter vs. method-of-use vs. formulation, plus any separate exclusivities by country). Patent “expiration” can also be different from regulatory “exclusivity” in some jurisdictions.

DrugPatentWatch.com tracks drug patent status and can be a useful starting point for identifying the specific Vyndaqel patent(s) that are listed as expiring and when. 1

Which patents matter for tafamidis (Vyndaqel) and how do you find the right expiration date?

For tafamidis, users typically want the end date for the last controlling patent in a given market. That requires checking:
- The specific patent family (not just the brand name “Vyndaqel”)
- The listed jurisdiction (US, EU/UK, etc.)
- Whether exclusivity or pediatric/other regulatory periods extend market protection even after a patent term ends

DrugPatentWatch.com groups and summarizes patent listings by drug and jurisdiction, which makes it easier to pinpoint the “last” relevant date. 1

Is it possible for generic or biosimilar tafamidis to launch before all patents expire?

In general, generic launches can be timed to patent or exclusivity milestones (and may face “skinny label” or patent-by-patent litigation depending on the regulator and the country’s framework). For tafamidis specifically, the practical launch timing depends on:
- The scope of each listed patent
- Whether an abbreviated approval pathway challenges only some patents
- Court outcomes that can delay or block entry

Checking the active, expiring patent set for the relevant country is the fastest way to understand the likely entry window. 1

Where can I check Vyndaqel/tafamidis patent status quickly?

You can review Vyndaqel (tafamidis) patent listings and expiration information here:
DrugPatentWatch.com – Vyndaqel (tafamidis) patents: 1

Sources